<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: J waves are the hallmark of both inferolateral early repolarization (ER) and <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>While <z:chebi fb="0" ids="28462">ajmaline</z:chebi>, a class 1a antiarrhythmic drug, accentuates the J wave in <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e>, its effect on ER is unreported </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To describe the effect of <z:chebi fb="0" ids="28462">ajmaline</z:chebi> on the electrocardiogram in ER </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed electrocardiograms before and after the administration of intravenous <z:chebi fb="0" ids="28462">ajmaline</z:chebi> (1 mg/kg) in 31 patients with ER, 21 patients with Brugada type 1 electrocardiogram (Br), and 22 controls </plain></SENT>
<SENT sid="4" pm="."><plain>ER was defined as J-point elevation of ≥1 mm with QRS slurring or notching in ≥2 inferolateral leads (I, aVL, II, III, aVF, V4-V6) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="28462">Ajmaline</z:chebi> decreased mean J-wave amplitude in the ER group from 0.2 ± 0.15 mV at baseline to 0.08 ± 0.09 mV (P &lt; .001) </plain></SENT>
<SENT sid="6" pm="."><plain>The QRS width prolonged significantly in <z:hpo ids='HP_0000001'>all</z:hpo> 3 groups, but the prolongation was significantly less in the ER group (+21 ms) than in the Br group (+36 ms; P &lt; .001) or controls (+28 ms; P = .010) </plain></SENT>
<SENT sid="7" pm="."><plain>Decrease in mean inferolateral R-wave amplitude was similar in <z:hpo ids='HP_0000001'>all</z:hpo> the groups (ER group -0.14 mV; Br group -0.11 mV; controls -0.13 mV; P = ns), but mean inferolateral S-wave amplitude increased significantly less in the ER group (ER group +0.14 mV; Br group +16 mV; controls +0.20 mV; P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="28462">Ajmaline</z:chebi> significantly decreases the J-wave amplitude in ER and prolongs the QRS width significantly less than in patients with Br </plain></SENT>
<SENT sid="9" pm="."><plain>This indicates a different pathogenesis for both disorders </plain></SENT>
<SENT sid="10" pm="."><plain>The altered terminal QRS vector probably is responsible for the decrease in the J-wave amplitude in ER, although a specific effect of <z:chebi fb="0" ids="28462">ajmaline</z:chebi> on J waves cannot be excluded </plain></SENT>
</text></document>